Intrinsic subtype and overall survival of patients with advanced HR+/HER2- breast cancer treated with ribociclib and ET: correlative analysis of MONALEESA-2, -3, -7.
Aleix PratNadia SolovieffFabrice AndreJoyce O'ShaughnessyDavid A CameronWolfgang JanniGabe S SonkeYoon Sim YapDenise A YardleyAnn H PartridgeAstrid ThuerigenJuan Pablo ZarateAgnes LteifFei SuLisa Anne CareyPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
The prognostic value of intrinsic subtypes for OS was confirmed in this pooled analysis of the MONALEESA trials (largest data set in HR+/HER2- ABC). While basal-like subtype did not benefit, a consistent OS benefit was observed with ribociclib added to ET across luminal and HER2E subtypes.